Taiwan Biomaterial Co., Ltd.
Research Taiwan Biomaterial Co., Ltd. (6649.TWO) on Bullrun: market cap TWD 1.54B, P/E 46.5, dividend yield 2.8%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker6649.TWO
- ExchangeTWO
- CountryTaiwan
- SectorHealthcare
- IndustryMedical Devices
- CurrencyTWD
- Market capTWD 1.54B
- P/E46.5
- Dividend yield2.8%
- Financial periodQ2 2026
- RevenueTWD 36.94M
- Net incomeTWD 622.00K
- Free cash flow-TWD 56.35M
- Gross margin48.6%
Valuation Snapshot
latest market cap is TWD 1.54B; P/E is 46.5; dividend yield is 2.8%.
Peer valuation comparison
Latest P/E is 46.52x versus a Healthcare sector median of 21.8x (113.4% above).
Latest dividend yield is 2.81% versus a Healthcare sector median of 2.4% (17.1% above).
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | TWD 1.54B | 46.5 | 2.7% | 1 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 1 TWD, yield 2.8%.
About Taiwan Biomaterial Co., Ltd.
Taiwan Biomaterial Co., Ltd. engages in the development and sale of implantable medical devices in Taiwan. It provides Foamagen, a foamagen dura substitute; stroke thrombus negative pressure removal catheter system comprising suction and removal of cerebrovascular embolism blood clot for the pump system, and nickel-titanium guidewire for guiding cerebral vascular surgery; tissue repair and regeneration products for the treatment of early osteoarthritis; and CDMO.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Taiwan Biomaterial Co., Ltd.'s market cap?
Taiwan Biomaterial Co., Ltd.'s market capitalization is TWD 1.54B.
What is Taiwan Biomaterial Co., Ltd.'s P/E ratio?
Taiwan Biomaterial Co., Ltd.'s price-to-earnings (P/E) ratio is 46.5.
Does Taiwan Biomaterial Co., Ltd. pay a dividend?
Taiwan Biomaterial Co., Ltd. has a dividend yield of 2.8%.
What does Taiwan Biomaterial Co., Ltd. do?
Taiwan Biomaterial Co., Ltd. engages in the development and sale of implantable medical devices in Taiwan. It provides Foamagen, a foamagen dura substitute; stroke thrombus negative pressure removal catheter system comprising suction and removal of cerebrovascular embolism blood clot for the pump system, and nickel-titanium guidewire for guiding cerebral vascular surgery; tissue repair and regeneration products for the treatment of early osteoarthritis; and CDMO. The company was founded in 1921 and is based in Zhubei, Taiwan.